Developed with CSIRO · Made in Australia · Est. 2022 · Patent Pending · TGA Approved
Precision-dosed.
Prescription ready.
Made in Australia.
Australia's first precision oral cannabinoid dosage unit — developed end-to-end with CSIRO, from debittering to dosing technology, backed by a world-first patent.
Developed with
the CSIRO
National Science Agency
100% Australian
Owned
Wholly Local Ownership
Made in Australia
from the best
Australian Grown & Made
A process that has
never existed before.
The process developed by HUM Australia in partnership with the CSIRO spans every stage of production — from the world-first molecular debittering technique, to THC isolate production, to pharmaceutical packaging design, to the exact dosing technology that guarantees ±2% accuracy in every unit. No other manufacturer — anywhere — has achieved this end-to-end scientific collaboration.
We are currently in the process of filing a global patent. When granted, it will be the only patent of its kind in existence.
Patent Pending
World-first process.
Global filing in progress.
100% Australian
Owned, developed,
and made in Australia.
The Science
The debittering
breakthrough.
Cannabis therapeutic compounds — cannabinoids and terpenes — are bound to bitter-tasting phenolic molecules that make oral administration deeply unpleasant. For decades, this has been one of the primary barriers to patient compliance. The medicine works, but patients cannot bear to take it.
Working with CSIRO — Australia's national science agency — across every stage of development, we built something that has never existed before. The debittering breakthrough was only the beginning. CSIRO's involvement extended to THC isolate production, pharmaceutical-grade packaging design, and the precision dosing technology that ensures every single unit delivers an exact, verified dose.
The result is not just a better-tasting extract — it is a fully validated, end-to-end pharmaceutical system. From the first molecule to the sealed foil unit in a patient's hand, every step has been developed, tested, and verified with Australia's national science agency.
0%
Bitter compounds removed
±0%
Dosing accuracy
5.00g
Identical weight, every piece
The Product
Designed to be
taken seriously.
Every element — from the formulation itself to the packaging it arrives in — has been engineered with pharmaceutical precision and the care of a world-class culinary team.
The Box
Six precision-dosed pieces in a pharmaceutical blister tray. Matte black exterior, gold foil branding.
The Seal
Individual CO₂-flushed aluminium foil blister. HUM+ branding with exact dose printed on every seal.
From Box to Dose
Sealed outer packaging. Pharmaceutical blister tray. Individual CO₂-flushed foil cavity. A single precision oral dosage unit with the exact dose embossed on the foil seal. Nothing left to chance.
Pharmaceutical Precision
Every piece.
The perfect dose.
Identical Weight
Each oral dosage unit is deposited into a pharmaceutical-grade stainless steel mould calibrated to produce a unit of exactly 5.00 grams. Weight is verified by an in-line precision scale accurate to ±0.05g.
CO₂ Sealed Foil
Each piece is sealed individually in a pharmaceutical-grade aluminium foil blister. The cavity is flushed with food-grade CO₂ to displace all oxygen, preserving potency and flavour without preservatives.
Batch Traceability
Every blister pack carries a unique batch number and QR code. Scan to access the full Certificate of Analysis — cannabinoid content, terpene profile, and all safety testing results.
The Process
Six steps from
extract to patient.
Every stage is controlled, documented, and independently verified. This is pharmaceutical manufacturing.
01
CSIRO Debittering
World-first molecular separation — developed with CSIRO under the leadership of Adj. Prof. Peter Duggan (now Director, Sunnybrae Consulting) — removes bitter phenolic compounds while preserving the complete cannabinoid and terpene profile.
02
Precision Dosing
Debittered extract is blended into the oral dosage base at precisely controlled temperature. Each batch is independently lab-tested for cannabinoid content.
03
Artisan Formulation
Our culinary director formulates each batch by hand using precision technique — controlling the base matrix for uniform distribution of the active cannabinoid compound.
04
Precision Moulding
The formulated base is deposited into pharmaceutical-grade stainless steel moulds. Each cavity is calibrated to produce a unit of exactly 5.00 grams.
05
Blister Sealing
Each piece is sealed in medical-grade aluminium foil. The cavity is flushed with food-grade CO₂ to displace all oxygen and eliminate oxidation.
06
Batch Certification
Every batch is independently tested and certified. A unique QR code on each blister links to the full Certificate of Analysis — cannabinoid content, terpene profile, and safety results.
The Craft
Crafted by a chef
who had to help.
When a world-class chef — whose restaurant holds a place in the global top ten — heard about HUM+, he didn't hesitate. His brother had been diagnosed with cancer. He knew what it meant to watch someone you love go through treatment.
He brought decades of experience in precision culinary formulation: tempering, moulding, emulsion ratios, the science of base matrix crystallisation. The result is an oral dosage unit that, if you didn't know what it was, you would simply call beautiful.
"If someone is going through the hardest thing in their life, the least we can do is make sure their medicine is something they look forward to."
Our Story
Built from loss.
Driven by love.
Tim, our founder, lost his mother to a brain tumour. Ross, his business partner and closest friend, lost his mother to the same disease. Two families. The same diagnosis. The same helplessness of watching someone you love in pain.
Both of them knew that medicinal cannabis could help. Both of them knew that the existing delivery formats — oils, capsules, vaporisers — were difficult to use, inconsistent in dosing, and deeply unpleasant to take.
They asked a simple question: what if medicine could be something a patient actually looked forward to?
That question led them to CSIRO, to a world-class chef, and eventually to HUM+. The name comes from the quiet, contented sound of someone who is comfortable. That is all we are trying to do: make people comfortable. Make people happy.
Our Provenance
From Australian soil
to Australian hands.
Step 01
Developed with
the CSIRO
CSIRO partnered with HUM+ across every stage of development — molecular debittering, THC isolate production, pharmaceutical packaging design, and precision dosing technology. The programme was led by Adj. Prof. Peter Duggan, formerly Senior Principal Research Scientist at CSIRO Botanical Pharmaceuticals and now Director of Sunnybrae Consulting, HUM+'s scientific and regulatory advisory firm.
Step 02
100% Australian
Owned
HUM Australia is wholly Australian owned and operated. No offshore investors. No foreign parent companies. Every decision is made here, for Australian patients.
Step 03
Made in Australia
from the best.
Every ingredient is sourced from Australian growers. Every oral dosage unit is manufactured in certified Australian facilities. From soil to seal — entirely local.
Strategic Partnership
Seeking Tier 1 status
with Montu.
Montu is Australia’s leading medicinal cannabis health-tech company — 150,000+ patients per year, 3,000+ partner pharmacies, and the fastest-growing tech company in Australia two years running. HUM+ is designed to be their first precision unit-dosed oral cannabinoid product.
What Tier 1 means
Tier 1 operators are the products that Montu’s network of doctors — through their Alternaleaf telehealth platform — actively prescribe to patients. It is the highest level of integration in their ecosystem.
Prescribed directly by Montu’s doctor network
Listed on the Alternaleaf patient platform
Distributed through Leafio to 3,000+ pharmacies
Fulfilled via uMeds to patients nationwide
Access to Montu’s 150,000+ patient base
Why HUM+ for Montu
HUM+ fills a gap that no product on the Montu platform currently occupies: a precision unit-dosed oral cannabinoid format that solves their #1 patient compliance problem.
Category creation
First precision-dosed oral cannabinoid dosage unit on any Australian platform
Compliance solved
Unit dosing eliminates the #1 reason patients abandon treatment
Recurring revenue
One piece/day = one box/month = a predictable, scalable prescription model
Exclusive potential
A world-first patent means no competitor can replicate the product
Prescriber confidence
End-to-end CSIRO partnership across debittering, THC isolate, packaging, and dosing technology — the deepest scientific credential in the category
The Montu Ecosystem — Where HUM+ Fits
HUM+
Product
Alternaleaf
Telehealth & Prescribing
Leafio
Wholesale Distribution
uMeds
Patient Fulfilment
Patient
150,000+ per year
For Prescribers
Designed for doctors
to prescribe with confidence.
HUM+ has been engineered from the ground up to meet the standards that prescribers, pharmacists, and regulators require. TGA approved. Every element of the product — from formulation to packaging — is designed to support clinical confidence across palliative care, oncology, chronic pain, anxiety, PTSD, sleep disorders, and beyond.
Exact Dose, Every Time
Each 5.00g oral dosage unit contains a precisely measured cannabinoid dose, verified by in-line pharmaceutical weighing. Dosing accuracy of ±2% — comparable to pharmaceutical tablets.
Full Certificate of Analysis
Every batch is independently tested. Each blister pack carries a QR code linking directly to the Certificate of Analysis — cannabinoid content, terpene profile, heavy metals, pesticides, and microbials.
Dual-Licenced Manufacturing
HUM+ is manufactured by PharmSky Research — a TGA GMP-licenced CDMO (licence granted July 2025) with full controlled substances capability. Manufacturing also operates under an ODC Narcotic Manufacturing Licence, satisfying Australia's unique dual-licence framework — one of the most demanding pharmaceutical manufacturing regimes in the world.
Improved Patient Compliance
The primary barrier to medicinal cannabis compliance is taste. HUM’s debittering process eliminates this entirely. Patients who enjoy taking their medicine take it consistently — improving outcomes.
Pharmaceutical-Grade Packaging
Individual CO₂-flushed aluminium foil blisters. Medical-grade outer carton. No recreational aesthetics. The packaging communicates medicine — because that is what it is.
Designed for Palliative Care. Built for Many More.
Born from personal loss — our founders lost their mothers to brain tumours. HUM+ was designed for palliative and oncology patients, but the precision dosing format is equally applicable to chronic pain, anxiety, PTSD, sleep disorders, and neurological conditions. One format. Many indications.
Request prescriber information.
HUM+ is TGA approved and building its prescriber network ahead of full commercial launch. Register below to receive clinical information, dosing guides, and early access to samples.
Register as a PrescriberManufacturing & Regulatory
Australia's most demanding
manufacturing standard.
HUM+ satisfies a dual-licence framework that most countries do not impose simultaneously — a TGA GMP licence governing pharmaceutical quality, and an ODC Narcotic Manufacturing Licence governing security. Both are required. Neither can substitute for the other.
Licence 1 of 2
TGA GMP Licence
Issued by the Therapeutic Goods Administration. Governs pharmaceutical quality — premises qualification, equipment validation, batch testing, quality management system, and data integrity. Requires on-site TGA inspection before grant, with unannounced re-inspections permitted at any time.
The TGA operates under the PIC/S gold standard — the same international framework used by the European Medicines Agency and the US FDA. Australia has been a PIC/S member since 1996.
Manufactured by PharmSky Research — TGA GMP licence granted July 2025
Licence 2 of 2
ODC Narcotic Manufacturing Licence
Issued by the Office of Drug Control under the Narcotic Drugs Act 1967. Governs what narcotic drug may be produced, in what quantities, and under what security conditions — including physical site assessments, personnel background checks, CCTV, access control, and chain-of-custody records.
Because HUM+ contains THC — a Schedule 8 controlled substance — the ODC security layer is mandatory. The manufacturing facility location cannot be publicly advertised.
Narcotic Drugs Act 1967 — UN Single Convention on Narcotic Drugs 1961
Manufacturing Partner
PharmSky Research
Dandenong South, VIC — a Melbourne-based CDMO offering end-to-end development and clinical manufacturing services (Phase I, II, and III). TGA GMP licence granted July 2025. One of Australia's few fully independent CDMOs with demonstrated controlled substances capability covering Schedule 8 and Schedule 9 medicines, medicinal cannabis, and psychedelics.
Full traceability from receipt through to despatch or destruction. Vendor qualification of controlled substance suppliers. Compliance with both TGA GMP and ODC narcotic licensing requirements under one roof.
Scientific & Regulatory Advisory
Sunnybrae Consulting
Scientific Advisor
Adj. Prof. Peter Duggan
Director & Founder — Sunnybrae Consulting Pty Ltd
One of Australia's foremost medicinal cannabis scientists. Formerly Senior Principal Research Scientist at CSIRO Botanical Pharmaceuticals, where he led the team that secured CSIRO's medicinal cannabis licence in 2021 — making CSIRO the only independent research institute in Australia able to develop drug manufacturing protocols in the medicinal cannabis space at that time.
Author of the landmark paper The Chemistry of Cannabis and Cannabinoids (Australian Journal of Chemistry, 2021). 117 research publications. 2,140+ citations. PhD Physical Organic Chemistry, ANU. Adjunct Professor, Flinders University.
Regulatory Affairs Advisor
Dr Sandhya Duggan
Regulatory Affairs Advisor — Sunnybrae Consulting Pty Ltd
Fifteen years of pharmaceutical regulatory affairs experience spanning Celgene, Commercial Eyes, and CSL Vifor. Her expertise is in preparing and managing TGA regulatory submissions, GMP compliance strategy, and product registration — the precise capabilities required to navigate HUM+'s pathway from clinical manufacturing to TGA registration and market access.
PhD Organic Chemistry, ANU. Post-doctoral research at the University of Cambridge and The Rockefeller University, New York.
Understanding Cannabis
Recommended reading.
History
From Ancient Medicine to Modern Pharmacy
A 5,000-year history of cannabis as medicine, from Chinese Emperor Shen Nung to the Australian TGA.
Science
The Endocannabinoid System Explained
How your body's own cannabinoid receptors interact with plant-derived compounds to modulate pain, appetite, and mood.
Regulation
Australia's Regulatory Journey
From prohibition to prescription: how Australia became one of the world's most progressive medicinal cannabis markets.
Get in Touch
Be among the first
to know.
Register your interest to receive updates on our launch timeline and prescriber information.
Your information is handled in accordance with Australian Privacy Principles. We will never share your details with third parties.
HUM Australia acknowledges the Traditional Custodians of the land on which we work and live, and pays respect to Elders past, present, and emerging. We recognise the deep knowledge of medicinal plants held by First Nations peoples for tens of thousands of years.